Chemed Corporation $CHE Stock Position Lowered by Algert Global LLC

Algert Global LLC decreased its position in Chemed Corporation (NYSE:CHE) by 28.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,435 shares of the company’s stock after selling 8,546 shares during the quarter. Algert Global LLC owned about 0.15% of Chemed worth $9,597,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. JPMorgan Chase & Co. lifted its holdings in Chemed by 122.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 499,968 shares of the company’s stock valued at $223,856,000 after acquiring an additional 275,423 shares during the last quarter. Norges Bank bought a new stake in shares of Chemed in the 2nd quarter worth approximately $89,388,000. AQR Capital Management LLC raised its holdings in shares of Chemed by 160.9% in the 2nd quarter. AQR Capital Management LLC now owns 201,041 shares of the company’s stock worth $97,893,000 after purchasing an additional 123,982 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Chemed by 740.9% during the third quarter. Arrowstreet Capital Limited Partnership now owns 95,573 shares of the company’s stock valued at $42,792,000 after purchasing an additional 84,208 shares during the last quarter. Finally, Epoch Investment Partners Inc. lifted its stake in Chemed by 29.4% during the third quarter. Epoch Investment Partners Inc. now owns 307,275 shares of the company’s stock valued at $137,579,000 after purchasing an additional 69,878 shares during the last quarter. Institutional investors own 95.85% of the company’s stock.

Chemed Stock Performance

Chemed stock opened at $402.03 on Monday. Chemed Corporation has a 52 week low of $385.00 and a 52 week high of $623.60. The firm has a market capitalization of $5.54 billion, a price-to-earnings ratio of 21.89, a P/E/G ratio of 1.59 and a beta of 0.47. The company has a 50 day moving average price of $441.48 and a 200 day moving average price of $440.81.

Chemed (NYSE:CHE) last announced its earnings results on Wednesday, February 25th. The company reported $6.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.02 by ($0.60). The firm had revenue of $639.34 million for the quarter, compared to analyst estimates of $659.09 million. Chemed had a net margin of 10.48% and a return on equity of 25.66%. Chemed’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period last year, the firm earned $6.83 earnings per share. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. Equities analysts forecast that Chemed Corporation will post 21.43 earnings per share for the current fiscal year.

Chemed Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 13th. Investors of record on Monday, February 23rd were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, February 23rd. Chemed’s dividend payout ratio is currently 13.06%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on CHE. Zacks Research lowered shares of Chemed from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 4th. Oppenheimer cut their price objective on Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research note on Wednesday, January 21st. Royal Bank Of Canada restated a “sector perform” rating and issued a $422.00 target price (down from $572.00) on shares of Chemed in a report on Friday, February 27th. Finally, Jefferies Financial Group lowered Chemed from a “buy” rating to a “hold” rating in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $498.00.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $403.18, for a total transaction of $806,360.00. Following the completion of the sale, the chief executive officer directly owned 93,719 shares in the company, valued at approximately $37,785,626.42. This trade represents a 2.09% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 3.29% of the company’s stock.

Chemed Company Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.